Bucillamine


Concise Prescribing Info
Indications/Uses
Rheumatoid arthritis.
Dosage/Direction for Use
Adult : PO Initial: 100 mg/day.
Dosage Details
Oral
Rheumatoid arthritis
Adult: Initially 100 mg/day.
Adverse Reactions
Skin and kidney disorders; pemiphigus lesions.
Action
Description: Bucillamine is structurally related to penicillamine & is reported to be an immunomodulator. It has been used in RA. It inhibits hypoxic induction of Vascular Endothelial Growth Factor (VEGF) through inhibition of Hypoxia Inducible Factor HIF-1 induction & binding activity in Bovine Retinal Microcapillary Endothelial Cells (BREC). It also inhibits the spontaneous expression of VEGF mRNA by its effect on Sp1 & Hypoxia Responsive Element (HRE) binding.
Disclaimer: This information is independently developed by MIMS based on Bucillamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in